Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 9, 2005

View Archived Issues

AstraZeneca: Q3 update

Introgen and Colgate-Palmolive form oral care alliance

Fovea completes Series A financing to develop drugs for retinal diseases

Emisphere receives FDA guidance on oral heparin phase III trial

OT-551 begins phase II trial in cataract prevention

Kos and Jerini sign agreement for icatibant in U.S. and Canada

Safety milestone in Osiris' stem cell trial for heart attack patients

Bionomics reviews operations

Mechanistic profile of Intermune's agents for IPF

Probenecid may halve the needed dose of oseltamivir

New tool to assess role of alpha1D- and alpha1B-ARs in prostate cancer

Hepcidin - a new target to prevent anemia of inflammation

Novel compounds with potential use in cardiovascular diseases reported

Not approvable letter for premature ejaculation drug dapoxetine

Recent patents disclose novel agents for dermatological disorders

Novel oligonucleotides for immunological disorders emerge from Coley R&D

Complement inhibition may reduce injury in coronary bypass surgery patients

Brivaracetam granted orphan drug status for symptomatic myoclonus

Meta-analyses reveal efficacy of gemifloxacin in resistant infections and high-risk patients

New data confirms the benefits of sitaxsentan in PAH

Update on the pharmacokinetics of alvimopan

A second phase III study confirms the therapeutic benefits of ranibizumab in AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...